Year

Author

Ref.

Study type

N

Applicability (%)

Therapy

Abnormal AFP value (ng/mL)

Study objective

AFP response (%)

AFP measure (w)

HR-MV (OS)

mOS^*

P (MV)

2005

Chen

[15]

Prospective

42

24

Thalidomide

>200

AFP response

>50

4

0.241

9.4/2.7

0.003

2009

Chan

[16]

Prospective

117

40

CT

>20

AFP response

>20

8

0.413

13.5/5.6

<0.0001

2009

Vora

[14]

Prospective

107

16.8

CT-TT

Any

AFP response

>50

4

NR

13/6.3

0.004

2010

Shao

[17]

Prospective

72

17

CT-TT

>20

AFP response

>20

2

0.356

15.3/4.1

0.019

2011

Yau

[18]

Prospective

94

54.3

Sorafenib

>20

AFP response

>20

6

0.3

NA/5.35

0.05

2012

Personeni

[19]

Retrospective

85

37.6

Sorafenib

>20

AFP response

>20

8

0.52

13.3/8.2

0.009

2012

Kawaoka

[20]

Retrospective

66

39

Sorafenib

>20

Measurement of AFP

>1 or <1^*

8

NR

12/6

0.001

2013

Nakazawa

[21]

Retrospective

59

54

Sorafenib

Any

AFP response

>20

4

4.14

NR

0.001

2014

Varela

Actual

Prospective

114

93.9

Sorafenib

>10

TPA

NR

12

2.42

18.8/8.1

0.001